 |
|
|
|
Sequential Therapy Appears to be Better than Triple Therapy in Eradicating H. pylori
|
|
|
|
An article published last year in the American Journal of Gastroenterology and recently reviewed by the Centre for Reviews and Dissemination has concluded that Sequential Therapy appears to be better than triple therapy in the eradication of Helicobacter pylori infection.
In their meta-analysis, the authors reviewed an extensive list of randomized controlled trials (RCTs) or controlled clinical trials that compared sequential therapy with triple therapy (lasting at least seven days), in patients who had not received previous treatment for Helicobacter pylori infection and had a follow-up test to confirm eradication. Follow-up testing was performed using the 13C Urea Breath Test due to its ability to detect active H. pylori infection.
In all, thirteen RCTs were included in meta-analyses (n=3,271 patients). For adult patients, sequential therapy was associated with a significant increase in eradication of Helicobacter pylori infection compared with triple therapy (OR 2.99, 95% CI 2.47 to 3.62; NNT 6, 95% CI 5 to 7; ten RCTs; n=3,011 patients). No significant heterogeneity was found for these outcomes. Moreover, there was no significant difference in the rate of side effects between sequential therapy and triple therapy.
|
|
|
|
|
|
|
|
|
H. pylori Association to Gastritis, Intestinal Metaplasia and Barrett’s Metaplasia
|
|
|
|
In a national study of H. pylori infection in gastric biopsy specimens, which included a sample size of 78,985 biopsy specimens, it was found that H. pylori infection, chronic active gastritis, and intestinal metaplasia had similar epidemiologic patterns and that the presence of each, based on histology analyses, was significantly associated with that of the others. However, these were inversely associated with Barrett’s metaplasia (less frequent in patients with Barrett’s metaplasia).
|
|
|
|
|
 |
|
Abstract |
|
|
|
First-line H. pylori Treatment Less Successful in Younger Patients
|
|
|
|
Helicobacter pylori eradication therapy is more successful in older patients than in younger ones. This was the finding in a recent Japanese study published in the World Journal of Gastroenterology.
|
|
|
|
|
|
|
Abstract |
|
|
|
Vitamin B6 Needed for Chronic Helicobacter Pylori Infection
|
|
|
|
According to scientists, Helicobacter pylori, a bacteria linked to ulcers and some types of stomach cancer, requires vitamin B6 to thrive and keep up chronic infection. In research published recently in the online journal mBio™, scientists also identified the enzymes needed to use the vitamin.
|
|
|
|
|
|
|
Abstract |
|
|
|
Exalenz Biosciences Ltd. Is not the author of the essays and articles appearing in this section of the newsletter and does not either sponsor or endorse their authors.
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
Advanced Technology for H. pylori Diagnosis. |
|
|
|
 |
|
|
|
|
|
 |
|
|
|
|
|
• |
|
Sensitivity and specificity of more than 99%
|
|
|
|
|
|
• |
|
10 minute test
|
|
|
|
|
|
• |
|
Immediate results
|
|
|
|
|
|
• |
|
Minimal staff time
|
|
|
|
|
|
• |
|
Minimal patient cooperation
|
|
|
|
|
|
Exalenz Bioscience Ltd. develops and markets advanced systems that extract vital information for diagnostics from subtle changes in patients’ exhaled breath.
Our proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.
|
|
|
|
